Search Within

Advanced Practice Providers

  1. "Alison Moskowitz"
Formats
  1. Meeting Abstract (36)
  2. Journal Article (14)
Groups
  1. Center for Hematologic Malignancies (50)
  2. Department of Medicine (50)
  3. Hematologic Malignancies, Division of (50)
  4. Lymphoma (50)
  5. Population Sciences Research Program (41)
  6. Survivorship Research (34)

More Groups

People
  1. Alison Moskowitz (50)
  2. Steven Horwitz (41)
  3. Andrew Zelenetz (34)
  4. Ariela Noy (32)
  5. Paul Hamlin (29)
  6. Anita Kumar (28)

More People

Years
  1. 2025 (2)
  2. 2024 (3)
  3. 2023 (6)
  4. 2022 (2)
  5. 2021 (5)
  6. 2020 (4)

More Years

Publications
  1. Blood (27)
  2. Journal of Clinical Oncology (7)
  3. Hematological Oncology (5)
  4. Annals of Oncology (2)
  5. Leukemia and Lymphoma (2)
  6. American Journal of Hematology (1)

More Publications

Publishers
  1. American Society of Hematology (27)
  2. American Society of Clinical Oncology (7)
  3. Wiley Blackwell (5)
  4. Oxford University Press (2)
  5. Taylor & Francis Group (2)
  6. American Association for Cancer Research (1)

More Publishers

Results (50)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Multispectral immunofluorescence identifies pS6 as a biomarker of intrinsic resistance to ruxolitinib in patients with relapsed/refractory T-cell lymphomas
    Meeting Abstract

    Ghione, P.; Moskowitz, A.; Kumar, P.; Knezevic, A.; Seshan, V.; Jacobsen, E.; Ruan, J.; Schatz, J.; Noor, S.; Myskowski, P.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Alternative anti-CD20 antibody versus desensitization for lymphoma patients with drug hypersensitivity reactions requiring discontinuation of rituximab, obinutuzumab, or ofatumumab
    Meeting Abstract

    Ghione, P.; Joffe, E.; De Paola, N.; Mainardi, T.; Noor, S. J.; Bobillo, S.; Myskowski, P. L.; Palomba, M. L.; Moskowitz, A. J.; Mato, A. R.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Long-term follow-up confirms durability of single-agent brentuximab vedotin as pre-transplant salvage for classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Schoder, H.; Lee, J.; Davey, T.; Hancock, H.; Hamlin, P. A.; Horwitz, S. M.; Kumar, A.; Matasar, M. J.; Noy, A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Final results of a phase II biomarker-driven study of ruxolitinib in relapsed and refractory T-cell lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Ghione, P.; Jacobsen, E. D.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Hancock, H.; Davey, T.; Obadi, O.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin combined with AVD chemotherapy and radiotherapy in patients with newly diagnosed early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L. E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S.; Drill, E.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A phase II, multicenter study of high dose chemotherapy with autologous stem cell transplant followed by maintenance therapy with romidepsin for T-cell lymphoma
    Meeting Abstract

    Khan, N.; Shustov, A. R.; Khimani, F.; Shadman, M.; Cassaday, R. D.; Ruan, J.; Moskowitz, A. J.; Zelenetz, A. D.; Noy, A.; Straus, D. J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Guillain Barré syndrome heralding the diagnosis of angioimmunoblastic T-cell lymphoma
    Journal Article

    Pathak, P.; Perimbeti, S.; Ames, A.; Moskowitz, A. J.
    Leukemia and Lymphoma (2019)

    Fulltext@MSK | Save
  • The combination of duvelisib, a PI3K-δ,γ inhibitor, and romidepsin is highly active in relapsed/refractory peripheral T-cell lymphoma with low rates of transaminitis: Results of parallel multicenter, phase 1 combination studies with expansion cohorts
    Meeting Abstract

    Horwitz, S. M.; Moskowitz, A. J.; Jacobsen, E. D.; Mehta-Shah, N.; Khodadoust, M. S.; Fisher, D. C.; Myskowski, P.; Wang, E. B. K.; Tawa, M.; Davey, T.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Durable responses observed with JAK inhibition in T-cell lymphomas
    Meeting Abstract

    Moskowitz, A. J.; Jacobsen, E.; Ruan, J.; Schatz, J. H.; Obadi, O.; Motylinski, K.; Jarjies, C.; Galasso, N.; Hancock, H.; Davey, T.; more...
    Blood (2018)

    Fulltext@MSK | Save